{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'The ICF and any other written information provided to subjects will be revised whenever', \"important new information becomes available that may be relevant to the subject's consent, or\", 'there is an amendment to the protocol that necessitates a change to the content of the subject', 'information and/or the written ICF. The Investigator will inform the subject of changes in a', 'timely manner and will ask the subject to confirm his/her participation in the study by signing the', \"revised ICF. Any revised written ICF and written information must receive the IRB/IEC's\", 'approval/favorable opinion in advance of use.', \"All signed ICFs are to remain in the Investigator's site file or, if locally required, in the subjects'\", 'notes/files of the medical institution.', 'The electronic case report forms (eCRFs) for this study contain a section for documenting all', 'subject informed consents, and this must be completed appropriately. If new safety information', 'results in significant changes in the risk/benefit assessment, the consent form should be reviewed', 'and updated if necessary. All subjects (including those already being treated) should be informed', 'of the new information, given a copy of the revised form and give their consent to continue in the', 'study.', '5.4', 'Compensation for Health Damage of Subjects/Insurance', 'The Sponsor maintains clinical trial insurance coverage for this study in accordance with the', 'laws and regulations of the country in which the study is performed.', '5.5 Confidentiality', 'All records identifying the subject will be kept confidential and, to the extent permitted by the', 'applicable laws and/or regulations, will not be made publicly available.', 'Subject names will not be supplied to the Sponsor. Only the subject number will be recorded in', 'the eCRF, and if the subject name appears on any other document, it must be obliterated before a', 'copy of the document is supplied to the Sponsor. Study findings stored on a computer will be', 'stored in accordance with local data protection laws. As part of the informed consent process, the', 'subjects will be informed in writing that representatives of the Sponsor, IRB/IEC, or regulatory', 'authorities may inspect their medical records to verify the information collected, and that all', 'personal information made available for inspection will be handled in strictest confidence and in', 'accordance with local data protection laws.', \"If the results of the study are published, the subject's identity will remain confidential.\", 'The Investigator will maintain a list to enable subjects to be identified.', '6', 'INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE', 'The Sponsor of this study is Horizon Pharma USA, Inc. (Horizon). Horizon personnel will serve', \"as the Medical Monitor and the Sponsor's regulatory representative (see Section 17.1 for details).\", \"The Sponsor's regulatory representative will be responsible for timely reporting of serious\", 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 43 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'adverse events (SAEs) to regulatory authorities as required. The Sponsor will be responsible for', 'timely reporting of SAEs and any other new pertinent safety information to all Investigators as', 'required.', 'The study will be conducted at up to 16 study centers in the United States and Europe, and the', 'Coordinating Principal Investigators (CPIs) will be', 'at the', 'in the US and', 'in the EU (Table 6.1). Prior to initiation of the study, each', 'Principal Investigator will provide the Sponsor or its designee with a fully executed and signed', 'Food and Drug Administration (FDA) Form 1572 and a Financial Disclosure Form. Financial', 'Disclosure Forms will also be completed by all sub-investigators listed on the Form 1572. It is', 'the responsibility of the Investigators or sub-investigators to advise the Sponsor of any change in', 'the relevant financial interests that occur during the study and the one-year period following its', 'completion.', 'The study will be monitored by a Data Safety Monitoring Board (DSMB), which will advise the', 'Sponsor regarding the continuing safety of study subjects and potential subjects as well as', 'continuing validity and scientific merit of the trial. Table 6.1 lists other organizations that are', 'critical to the conduct of the study, with a brief description of their roles:', 'Table 6.1', 'Table of Non-Sponsor Study Responsibilities', 'Study Responsibility', 'Organization', 'Coordinating Principal Investigator (CPI)', 'Contract research organization (CRO)', '(monitoring, data management, statistical', 'analysis, and pharmacokinetic [PK] analysis)', 'Interactive Web Response System (IWRS)', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 44 of 117']\n\n###\n\n", "completion": "END"}